Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity

Study Identifier
191622-056
CT.gov Identifier
NCT00651729
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Stroke
  • Movement Disorders - Other
    • Study Drug
  • Botulinum Toxin Type A
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    21+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Medically stable poststroke patients with spastic muscles in the upper limb
    Exclusion Criteria:
    * Stroke within 6 months of study enrollment * Previous therapy with Botulinum Toxin Type A for treatment of any condition prior to 4 months of enrollment, for treatment of any condition prior to 01 January 1998

    Protocol Summary

    The purpose of this study is to evaluate the safety of repeated doses of Botulinum Toxin Type A for the treatment of focal upper limb poststroke spasticity

    Study Locations

    Location
    Status
    Location
    Indianapolis, Indiana, United States
    Status
    Not applicable
    Location
    Vancouver, British Columbia, Canada
    Status
    Not applicable